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Most of drugs could have certain mucocutaneous reactions and COVID-19 drugs
are not an exception that we focused. We systematically reviewed databases
until August 15, 2020 and among initial 851 articles, 30 articles entered this
study (20 case reports, 4 cohorts, and 6 controlled clinical trials). The types of
reactions included AGEP, morbiliform drug eruptions, vasculitis, DRESS syndrome,
urticarial vasculitis, and so on. The treatments have been used before side effects
occur, included: antimalarial, anti-viral, antibiotics, tocilizumab, enoxaparin and and
so on. In pandemic, we found 0.004% to 4.15% of definite drug-induced mucocu-
taneous reactions. The interval between drug usage and the eruption varied
about few hours to 1 month; tightly dependent to the type of drug and
hydroxychloroqine seems to be the drug with highest mean interval. Antivirals,
antimalarials, azithromycin, and tocilizumab are most responsive drugs for adverse
drug reactions, but antivirals especially in combination with antimalarial drugs are
in the first step. Types of skin reactions are usually morbilliform/exanthematous
maculopapular rashes or urticarial eruptions, which mostly may manage by ste-
roids during few days. In the setting of HCQ, specific reactions like AGEP should
be considered. Lopinavir/ritonavir is the most prevalent used drug among antivi-
rals with the highest skin adverse reaction; ribarivin and remdisivir also could
induce cutaneous drug reactions but favipiravir has no or less adverse effects.
Logically the rate of dermatologic adverse effects among anivirals may relate to
their frequency of usage. Rarely, potentially life-threatening reactions may occur.
Better management strategies could achieve by knowing more about drug-
induced mucocutaneous presentations of COVID-19.
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Although COVID-19 does not have any targeted specific therapies
for virus itself, but there are many proposed drug categories for
using in this pandemic, each one affects on one or more well-known
pathomechanisms of viral infection or infection-induce conse-
quences. The most important drug categories for new coronavirus
are: Antimalarials (Chloroquine, hydroxychloroquine), Azithromycin,
Antivirals (Remdesivir, Oseltamivir/Favipiravir/Umifenovir, Ribavi-
rin, Lopinavir/Ritonavir, sofosbuvir, nitazoxanide), biologic or chem-
ical targeted therapies (janus kinase inhibitors, TNF-a inhibitors,
Tocilizumab, Anakinra, Checkpoints inhibitors, Camostat mesylate),
Classic Immunomodulators (Colchicine, Interferons, Corticosteroids,
IVIG) and the Vaccines. Among these drugs, some affect virus itself,
some affect virus-associated cytokine storm, immune dysregulation
and organ failures and some (eg, Azithromycin) other than their
anti-inflammatory characteristics, may positively affect on concomi-
tant complications like possible bacterial infection.1
Naturally, every drug or drug category has its own adverse effects
including mucocutaneous drug reactions that some of them are more
prevalent, popular or serious. Dermatologist should aware of these
drug-related mucocutaneous reactions for better approach to the
COVID-19 affected patients during pandemic especially in the case of
counseling cases.
1.2 | Objective
There are few reports about treatment-related mucocutaneous drug
reactions of COVID-19, but since this infection is a pandemic concern
with an increasing infection rate at many areas of the world, it is
expected to encounter growing reports of drug-related adverse muco-
cutaneous reactions, such as, HCQ-induced AGEP or flare and aggra-
vation of psoriasis course.2,3 In overall, different types of drug
categories, which may use for treatment of new corona virus with
their own well-known dermatologic reactions also patients who are in
a certain condition results from the virus and host interaction-induced
immune-dysregulation and cytokine storm may provide higher ten-
dency to emergence of well-known, new, severe and more complex
mucocutaneous drug reactions or even aggravation and flare of a pre-
existing dermatoses. So, in this systematic review, we focused on the
treatment-related mucocutaneous drug reactions of COVID-19, to
discuss on the clinical presentation types, differential diagnoses,
severity, course, definite diagnosis and the managements or probable
challenges.
2 | MATERIALS AND METHODS
2.1 | Protocol and registration
This study is implemented according to the PRISMA (Preferred
Reporting Items for Systematic Reviews and Meta-Analyses) state-
ment. The PRISMA flow chart has been shown in Figure S1 in the
supplement file.
2.2 | Eligibility criteria
Inclusion criteria comprised all studies that report mucocutaneous
drug reaction or skin and dermatologic manifestation in response to
treatment of COVID-19 patients. PICO: population was COVID-19
patients, intervention was COVID-19 treatment, comparison was
COVID-19 patients without taking any special treatment and outcome
was mucocutaneous manifestations. The exclusion criteria consisted
of animal studies, in vitro studies, review studies and all publications
not meeting the above.
2.3 | Information sources
Databases PubMed (http:// pubmed.ncbi.nlm.nih.gov), Scopus (http://
www.scopus.com), Embase (https://www.embase.com) and Google
Scholar (https://scholar.google.com) and CEBD Covid-19 Resource
for Dermatology (https://skin.cochrane.org/news/cebd-covid-19-
resource-dermatology) have been searched for the evidence.
2.4 | Search strategy
The search was performed by keywords COVID-19, corona viruses,
COVID-19 symptoms, novel corona virus, corona virus pneumonia,
corona virus disease, severe acute respiratory syndrome corona virus
2 and skin manifestations, drug reaction, adverse drug eruption,
adverse drug reaction. Search was not limited to the entries to any
condition. The search started and completed on August 15, 2020. The
period of search was any articles published until August 15, 2020. The
search strategy has been shown in Table S1.
2.5 | Study selection
Endnote X9 (Clarivate Analytics, Philadelphia) was used for study
screening and data extraction. 851 articles assigned to the inclusion
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and exclusion groups. In first step, the titles and abstracts of articles
were read. And, if accepted has evaluated to second step; 186 articles
went to the full-text screening; the authors read the full-text and exe-
cuted the final inclusion articles. Disagreement situations regarding
the inclusion process resolved through dialogue and no necessity for a
third-party involvement occurred.
3 | RESULT
3.1 | Study selection
Finally, there were 30 articles that met inclusion criteria and the infor-
mation of these articles are prepared in Tables 1-4.
3.2 | Study characteristics
We have evaluated 20 case reports including 25 cases of COVID-19
who were treated with multiple drugs in Table 1.4-23 In Tables 2, 4
cohort studies are shown. In cohort studies based on the drugs have
been used the overall rate of mucocutaneous dermatologic eruptions
ranged from 0.004% to 4.15%. Antivirals, antimalarials, azithromycin,
and tocilizumab were most responsive drugs for adverse reactions. It
seems that antivirals especially in combination with antimalarial drugs
may have the highest rate of skin reactions. Types of skin reactions
are usually morbilliform/exanthematous maculopapular rashes or urti-
carial eruptions. Pruritus, bullous rashes and skin dyspigmentations
were other observed dermatologic adverse effects of drugs used for
management of COVID-19.24-28
Table 5 shows cohort studies reported dermatologic rashes in the
setting of COVID-19 but with uncertainty about exact origin; means
that exactly say about they were virus-related or drug-related.28 The
reported mucocutaneous reaction rate in these series of studies was
about 5.7% to 45.5%, and the drugs were suspected as the cause of
these drug reactions were mainly antimalarials, antivirals,
azithromycin, systemic steroids, and tocilizumab with different preva-
lence distributions in various studies. Antimalarials, antivirals,
azithromycin were the most prevalent drugs used for therapy and
morbilliform/exanthematous maculopapular, purpuric, EM-like and
PR-like eruptions were the most observed mucocutaneous reactions
of these drugs.28
In Tables 3 and 4 controlled clinical trial studies have been shown
which were 5 articles with 2 arms [29-33]and 1 article with 3 arms.34
It seems that favipiravir has no or less skin adverse reactions in com-
parison with lopinavir/ritonavir. Remdisivir could induce mucocutane-
ous rash but the most probable cause of skin reactions between
antivirals is related to lopinavir/ritonavir (21%). Ruxolitinib is another
drug may cause mucocutaneous reactions (10%). Interferon-alfa my
decrease rate of dermatologic reactions of antivirals such as ribavirin
or lopinavir/ritonavir based on what we observed in combination
therapy regimens. Logically it should be notified that the rate of der-
matologic adverse effects among anivirals may relate to their
frequency of usage and since lopinavir/ritonavir at the time of data
gathering of this systematic review was the most prevalent used ant-
iviral; so it is not unexpected to see the most dermatologic reactions
among antivirals by this drug.
3.3 | Result of individual studies
In the antimalarials group; Acute generalized exanthematous
pustulosis (AGEP), flares and exacerbations of psoriasis, urticaria,
exanthematous rash, pruritus, dry skin, exfoliations, Stevens-Johnson-
like syndrome, alopecia and hair whitening and mucocutaneous dys-
pigmentation, In the Antivirals group; Maculopapular or eczematous
rash, exfoliative erythroderma, urticaria, angioedema, allergic or idio-
syncratic cutaneous drug reactions, annular erythema and photosensi-
tivity, skin dryness, pruritus and redness, SJS, 10 injection site
reactions, localized scleroderma, lichenoid drug eruption, bite hyper-
sensitivity, lipodystrophy, nail, oral, mucosa and skin hyper-
pigmentation, Hair loss and alopecia, paronychia and acneiform
eruptions were the known reported dermatologic side effects. In bio-
logic or chemical targeted therapies group; morbilliform or eczema-
tous rash, urticaria, angioedema, photosensitivity, skin
hypersensitivity reactions, exfoliations, psoriasis and psoriasiform-like
lesions, palmoplantar pustulosis-like eruption, lupus-like syndromes,
cutaneous vasculitis, lichenoid eruptions, pruritus, xerosis, injection or
infusion-site reactions, alopecia, stomatitis, hyperhidrosis, vitiligo, hair
color changes, impaired wound healing, periungual pyogenic
granuloma-like lesions, various granulomatous reactions (sarcoidosis-
like reactions, granulomatous panniculitis, granuloma annulare and
granulomatous dermatitis…), skin infections (eg, infection of wounds,
cellulitis, herpes zoster and herpes simplex activations…), melanoma
and nonmelanoma skin cancers and cutaneous lymphoma, have been
reported. In Classic Immunomodulators group; Anaphylactic reaction,
diffuse, blanchable, violaceous, morbilliform rash, urticaria, mac-
ulopapular rash, eczematous drug reactions, psoriasis, lichenoid drug
reactions, erythema multiforme, toxic epidermal necrolysis-like reac-
tion, erythema-bullous and erythema-nodosum-like lesions, sarcoido-
sis, lupus, cutaneous vasculitis lesions, petechiae, injection site
reactions, alopecia and hirsutism, transient and mild to moderate pru-
ritus, dryness, burning, stinging, erythema, oedema, fissures, folliculi-
tis, acneiform eruptions, papular and pustular lesions, skin atrophy,
striae, telangiectasia and disease exacerbation, could be seen.
Azithromycin may cause cutaneous severe skin reaction associated
fever, angioedema, anaphylaxis, DRESS syndrome, generalized red or
purple skin rash, blistering, skin peeling, fixed drug eruptions, toxic
pustuloderma, eye burning, skin pain and cutaneous leukocytoclastic
vasculitis.1,35-39
AGEP was reported in three patients with hydroxychloroquine
treatment on average 10 days after taking the drug, in one patient
with Lopinavir/Ritonavir treatment and one patient with cefditoren
treatment. we should consideration that Pustular Psoriasis (PP) and
acute generalized exanthematous pustulosis (AGEP) are clinically
resemble each other. So, in patients specially with psoriasis history











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































8 of 16 NOBARI ET AL.
that take hydroxychloroquine for covid-19 treatment, generalized
pustular presentations like hydroxychloroquine-induced pustular reac-
tion who do not completely fall within PP or AGEP categories.40
4 | DISCUSSION
There are some studies reporting aggravation course of a pre-existing
dermatologic disorders which have induced by the treatment of
COVID-19 that one of the well-known entities in this area is aggrava-
tion of psoriasis by HCQ.6 But the focus of this study is on newly
emerging COVID-19 treatment-related mucocutaneous drug reac-
tions. Due to the fact that there is still no specific treatment protocol
for patients with COVID-19, the use of multiple treatments is still
common even inevitable for these patients. In addition, some of these
drugs, such as, hydroxychloroquine, can have many potential side
effects, such as, acute generalized exanthematous pustulosis
(AGEP).35,36 Dermatologic lesions in patients with COVID-19 may be
the mucocutaneous manifestation of virus disease and the related
consequences itself or could be due to drug reactions.12 In evaluation
of the mentioned case reports, the incidence of drug reactions in
these patients is not rare even speedily growing in the literatures.
However, these side effects were controlled by withdrawal of respon-
sible drug and usually with concomitant use of topical or systemic ste-
roids and antihistamines. Based on Table 1 about case reports of
dermatologic drug reactions in COVID-19 patients, we found that
these patients had no sign or symptoms of any pre-existing dermato-
logic disease at the onset of their disease and detailed information of
these cases are exist in Table 1 that here we describes some of them
for example: in the case report by Sernicola et al. they have reported
a drug reaction in the form of DRESS syndrome (itching generalized
cutaneous “toxic erythema-like” rash with eosinophilia) in few hours
after the administration of tocilizumab, which had improved with sys-
temic steroid.4 The patient recovered after 10 days. In the case report
by Robustelli Test et al. they reported a drug reaction in the form of
acute generalized exanthematous pustulosis (AGEP) 3 days after the
withdrawal of the treatment with Lopinavir/Ritonavir and hydro-
xychloroquine.5 The diagnosis confirmed with skin biopsy. In addition,
the patient had Erythema Multiform-Like lesions, too. The patient was
treated with systemic steroid. In another study by Litaim et al. A drug
reaction in the form of acute generalized exanthematous pustulosis
(AGEP) was reported 18 days after hydroxychloroquine initiation.6
Unfortunately, the patient was expired due to massive pulmonary
emboli. In the study by Skroza et al. they reported the drug reaction in
the form of Urticarial Vasculitis with the skin manifestation of multi-
ple, raised erythematous wheals, alone or in cluster, some of them
with central purple hyperpigmentation.7 The diagnosis was confirmed
by skin biopsy and the histopathology of drug reaction/Urticarial Vas-
culitis. The drug eruption occurred 4 days after administration of Cef-
triaxone, Lopinavir/Ritonavir, Enoxaparin and hydroxychloroquine.
The reaction was treated with oral Prednisone, Bilastine and Pan-
toprazole and the complete remission achieved in about a week. In


















































































































































































































































































































































































































































































NOBARI ET AL. 9 of 16
the form of vasculitis 2 days after administration of amoxicillin, ibu-
profen, metamizole, intravenous prednisolone and antihistamine.8 The
skin biopsy confirmed drug-induced vasculitis. The patient was
treated with high dose systemic steroid and complete remission was
achieved 9 days after treatment. According to case reports studies
drug dependent skin manifestations may occur a few hours to a
month after taking the drug and usually last less than a week. The
interval between drug usage and the eruption varies about few hours
to 1 month and it is tightly dependent on the type of drug was used;
hydroxychloroquine seems to be the drug with highest mean interval.
Antibiotics and antivirals (especially lopinavir/ritonavir) usually have
shorter lag times of mucocutaneous adverse eruptions in comparison
with HCQ, so we may expect COVID-19 related delayed drug erup-
tions even after discharge of patients that needs more awareness to
better management of patients. Based on cohort studies we may
expect 0.004% to 4.15% of definite drug-induced mucocutaneous
reactions but in the case with uncertainly about the origin of dermato-
logic reaction (as primary virus-induced or drug eruption), this rate
reaches to 5.7% to 45.5%.24-28 Antivirals, antimalarials, azithromycin
and tocilizumab are most responsive drugs for adverse drug reactions,
but antivirals especially in combination with antimalarial drugs are in
the first step and in this setting of therapy the clinicians may expect
the highest rate of mucocutaneous reactions. Types of skin reactions
are usually morbilliform/exanthematous maculopapular rashes and
urticarial eruptions which mostly may manage by steroids during few
days. Pruritus, bullous rashes, skin dyspigmentations, purpuric, EM-
like and PR-like eruptions are other probable observed dermatologic
adverse effects of drugs in COVID pandemic. Based on the best we
know, lopinavir/ritonavir is the most prevalent used drug with the
highest skin adverse reaction among antivirals, ribarivin and remdisivir
also could induce mucocutaneous drug reactions (about 10%). It
seems that favipiravir has no or less skin adverse reactions in compari-
son with lopinavir/ritonavir. Ruxolitinib is another drug may cause
mucocutaneous reactions (10%). Interferon-alfa my decrease rate of
dermatologic reactions of antivirals such as ribavirin or lopinavir/rito-
navir based on what we observed in combination therapy regi-
mens.29-34 It should be notified that logically the rate of dermatologic
adverse effects among antivirals is related to their frequency of usage,
TABLE 2 Cohort studies
First
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NOBARI ET AL. 13 of 16
too. Since, adverse drug reactions of skin are frequently observed in
pandemic area, dermatologist and specialists of other fields really
need to be more informed about drugs with more mucocutaneous
adverse reactions and the type of reactions and some of these reac-
tions may be severe or even life-threatening also management of
patients in such conditions could be really challenging regarding skin
eruption and concomitant COVID infection.4,19,20 The authors of this
study have been focused on various aspects of COVID-19 especially
in the field of dermatology and now it seems that focus on this topic
is of great importance. Some clinical and therapeutic features of
COVID-19 and its probable final sequels may become more clear and
evident during time especially about its virus-related or drug-related
mucocutaneous signs, which needs more focus in future studies also
discuss about management of patients with a specific dermatologic
disorder in the pandemic era, multi-potential drugs for Therapy, or
approach to the elective treatments of primarily common cutaneous
disorders or cutaneous presentations of systemic disorders especially
in elderly people may could be logically postponed; like cosmetic pro-
cedures, non-emergent surgeries or some chronic insignificant medical
skin disorders.39,41-44The field of COVID is of interest of the authors
of this review and they have focused to somehow on the all men-
tioned topics.45-47
5 | CONCLUSION
Given that the drugs used to treat COVID-19 could potentially have
several side effects, the incidence of mucocutaneous drug reactions in
these patients is not unexpected. In this pandemic, during treatment
with common therapeutic protocols for COVID-19, numerous derma-
tologic drug side effects should be considered and more investigate
for better diagnoses and approaches especially regarding the point
that large number of the patients may visit by physicians of multiple
services, so logically knowing more about the mentioned presenta-
tions is really of great value for many subspecialists even other than
the dermatologists.
Since the lack of enough evidence about treatment-related mucocu-
taneous drug reactions of COVID-19, we decided to systematically sea-
rch the literature for these types of dermatologic reactions. In future
perspective we expect encounter to growing reports of drug-related
adverse mucocutaneous reactions of COVID-19, which could be well-
known, new, severe or more complex due to the pandemic concerns,
new-emerging proposed therapies, increasing infection rate of new
corona virus at many areas of the world and also virus-host induced cer-
tain immune abnormalities that may affect the nature of the drug reac-
tions. We found that drug reactions in patients with COVID-19 could be
common and skin side effects is not an exception due to the multiplicity
of drugs and the type of drugs are used so the risk of drug reactions with
these drugs should be considered in any prescription treatment.
We found 0.004% to 4.15% of definite drug-induced mucocuta-
neous reactions in pandemic area. The interval between drug usage
and the eruption varies about few hours to 1 month tightly dependent
to the type of drug and usually last less than a week;
hydroxychloroqine seems to be the drug with highest mean interval.
Antivirals, antimalarials, azithromycin and tocilizumab are most
responsive drugs for adverse drug reactions, but antivirals especially
in combination with antimalarial drugs are in the first step. Types of
skin reactions are usually morbilliform/exanthematous maculopapular
rashes and urticarial eruptions which mostly may manage by steroids
during few days. In the setting of HCQ, specific reactions like AGEP
should be considered. lopinavir/ritonavir is the most prevalent used
drug with the highest skin adverse reaction among antivirals; ribarivin
and remdisivir also could induce cutaneous drug reactions but
favipiravir has no or less adverse effects. It should be notified that log-
ically the rate of dermatologic adverse effect among antivirals is
related to their frequency of usage, too. Although very rare, we may
encounter challenging sever or potentially life threatening mucocuta-
neous adverse drug reaction. Knowing more about the probable drug-
induced mucocutaneous presentations of COVID-19, is really of great
value for better management of encountered cases.
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